Avalon GloboCareNASDAQ: ALBT

Avalon GloboCare Corp (NASDAQ:ALBT) announced the extension of its exclusive distribution agreement with Qi Diagnostics for the KetoAir breathalyzer device and related accessories in several key regions, including North America, South America, the United Kingdom and the European Union.   Shares of the biotechnology company added 19% at US$0.36 before Thursday's opening bell on the news.

Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has engaged ChtrBx, a marketing and branding company, to develop a marketing launch plan for KetoAir in North America, South America, the United Kingdom (UK) and the European Union (EU).  The developer of innovative cell-based technology, cellular therapy and precision diagnostics said KetoAir functions as a companion diagnostic and monitoring device, combined with an artificial intelligence (AI) nutritionist consultation for ketogenic dietary management.

Avalon GloboCare Corp (NASDAQ:ALBT) shares rose in early trade after it announced a partnership with medical device company Qi Diagnostics to co-develop international multi-center clinical studies for the DKAir breathalyzer device for the early detection of diabetic ketoacidosis (DKA). Developed by Qi Diagnostics, the DKAir is a handheld breathalyzer that allows diabetic patients to detect the level of acetone in their breath.

Avalon GloboCare Corp (NASDAQ:ALBT) has officially unveiled its KetoAir mobile application on the Apple App Store. Coupled with an AI nutritionist and a nanosensor-based breathalyzer, KetoAir serves as a companion diagnostic and monitoring device for individuals practicing a ketogenic lifestyle The app, designed to facilitate ketogenic dietary management, is now also available for download on the Google Play store.

Avalon GloboCare Corp (NASDAQ:ALBT) announced that its 40% owned clinical diagnostics and reference lab Laboratory Services MSO (LSM) has made two significant accretive acquisitions: Merlin Medical Supply (MMS) and Leading Edge Innovations.  MMS is a home medical equipment and durable medical equipment company operating in Ventura County, California, which has contracts with major healthcare payers, including Medicaid, Medicare, Medi-Cal, Optum-Rx, CCS, Tri-Care, Blue Cross/Blue Shield, Humana, Aetna, United Health and Gold Coast.

Avalon GloboCare Corp (NASDAQ:ALBT) shares climbed 29% to $1.24 on Tuesday after the precision diagnostics and clinical laboratory services provider said it received a new US patent titled "QTY Fc Fusion Water Soluble Receptor Proteins," a collaborative effort with Dr Shuguang Zhang of the Massachusetts Institute of Technology (MIT), which encompasses the composition and methodology for a groundbreaking technology known as the "QTY Code."   According to the company, the QTY Code has the potential to transform water-insoluble transmembrane receptor proteins into their water-soluble counterparts, thereby expanding the horizon of therapeutic targets for conditions like cancer and diseases.

Avalon GloboCare Corp (NASDAQ:ALBT) has received a new patent to add to its portfolio. The Freehold, New Jersey-based company announced the United States Patent and Trademark Office (USPTO) issued a Notice of Publication for U.S.

Avalon GloboCare Corp (NASDAQ:ALBT) announced that its 40% owned Laboratory Services MSO, LLC (LSM) is now offering an in-house laboratory developed test (LDT) to detect tuberculosis (TB) using a patient's sputum sample.  The developer of innovative cell-based technology, cellular therapy and precision diagnostics said the new test method is expected to generate revenue in 2023.

Avalon GloboCare Corp (NASDAQ:ALBT) told investors that Laboratory Services MSO (LSM), in which it owns a 40% interest, is opening a new laboratory — Veritas Laboratories — in Scottsdale, Arizona.  The company noted that Veritas is a CLIA-certified and COLA-accredited laboratory that offers a wide range of high-quality testing, including drug testing, genetic testing, urinary testing and COVID-19 PCR testing.